Orano Med LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.arevamed.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Conditions
- Cervical CancerColon CancerNSCLCBreast CancerCutaneous MelanomaProstate Cancer Metastatic
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Orano Med LLC
- Target Recruit Count
- 55
- Registration Number
- NCT05283330
- Locations
- 🇺🇸
Northwestern University Robert H Lurie Medical Research, Chicago, Illinois, United States
🇺🇸UK Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Advanced Molecular Imaging and Therapy, Glen Burnie, Maryland, United States
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Orano Med LLC
- Target Recruit Count
- 69
- Registration Number
- NCT05153772
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Louisiana State University (LSU) Health Sciences Center - New Orleans, Metairie, Louisiana, United States
Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Orano Med LLC
- Target Recruit Count
- 33
- Registration Number
- NCT03466216
- Locations
- 🇺🇸
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
- Conditions
- Peritoneal NeoplasmsPancreatic NeoplasmsBreast NeoplasmsStomach NeoplasmsOvarian Neoplasms
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Orano Med LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01384253
- Locations
- 🇺🇸
University Of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸UCSD Moores Cancer Center, San Diego, California, United States